Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Marked radiosensitization of cells in culture to x ray by 5-chlorodeoxycytidine coadministered with tetrahydrouridine, and inhibitors of pyrimidine biosynthesis

Conference · · Int. J. Radiat. Oncol., Biol. Phys.; (United States)
OSTI ID:6500575
The authors approach to overcome the problem of rapid catabolism and general toxicity encountered with 5-halogenated analogues of deoxyuridine (5-bromo, chloro or iododeoxyuridine), which has limited their use as tumor radiosensitizers, is to utilize 5-chlorodeoxycytidine (CldC) with tetrahydrouridine (H/sub 4/U). They propose that CldC, coadministered with H/sub 4/U, is metabolized in the following manner: CldC ..-->.. CldCMP ..-->.. CldUMP ..-->.. ..-->.. CldUTP ..-->.. DNA. All the enzymes of this pathway are elevated in many human malignant tumors and in HEp-2 cells. In x irradiation studies with HEp-2 cells, limited to 1 or 2 radiation doses. They obtained 3.0 to 3.8 apparent dose enhancement ratios when cells were preincubated with inhibitors of pyrimidine biosynthesis. Enzymatic studies indicate that this toxicity may be tumor selective. Preliminary toxicity studies indicate that mice will tolerate treatment protocols with marginal weight loss (4%). In this approach the authors seek to obtain preferential conversion of CldC to CldUTP at the tumor site by taking advantage of quantitative differences in enzyme levels between tumors and normal tissues.
Research Organization:
Univ. of Miami, FL
OSTI ID:
6500575
Conference Information:
Journal Name: Int. J. Radiat. Oncol., Biol. Phys.; (United States) Journal Volume: 10:8
Country of Publication:
United States
Language:
English

Similar Records